GSK will fund only independent medical education programs that are clearly designed to close gaps in patient care, and that demonstrate support for the optimal performance of healthcare professionals effective January 2010.
GSK has implemented a new approach to valuing donations as average cost of goods rather than the wholesale acquisition cost. Effective December 1, 2008.
GSK announced in July 2009 that it intends to invest up to £50 million over 10 years to try to prevent mother-to-child transmission of HIV in Sub-Saharan Africa. GSK will also partner with other Pharma companies to create new medicines for children and adults living with HIV/Aids.
GSK is reducing its prices for patented medicines in Least Developed Countries (LDCs) so they are no higher than 25 per cent of the price in the developed world providing this covers the cost of goods. Effective April 1, 2009.
GSK will reinvest 20 per cent of profits made from selling medicines in LDCs to support the strengthening of healthcare infrastructure in these countries. Effective April 1, 2009.
GSK will partner with other pharmas and biotech companies that have patents developed to treat diseases that are prevalent in developing countries. Effective March 24, 2009.
Starting in 2011, GSK will disclose payments made in 2010 to Healthcare professions and institutions in the US.
Post Observational studies, meta-analyses and studies of terminated compounds on the GSK Study Register
This posting supplements communication in journals, at scientific meetings, in letters to healthcare professionals, and in approved prescribing information. Effective January 1, 2009.
Publish all clinical research results in the scientific literature
GSK will publish all clinical research of its medicines either as manuscripts in peer-reviewed journals or, when studies are not published, provide context and interpretation on the GSK Clinical Study Register. Effective January 1, 2009.
Report clinical trial investigator names and institutions
GSK will publish the names of investigators in GSK-sponsored clinical trials and the institutions they are working in, on registers of clinical trial protocols for studies starting January 2009.
Alnylam joins patent pool for neglected tropical diseases
Alnylam Pharmaceuticals, Inc. announced July 8, 2009, that it will contribute more than 1500 issued or pending patents on its RNA interference (RNAi) technology patent estate to the patent pool established by GSK earlier this year.
Effective January 1, 2009, GSK voluntarily stopped all corporate political contributions. In the US, GSK will continue to support a voluntary and independent political action committee to facilitate political contributions by eligible employees.
Healthcare providers are paid by GSK for speaking on its behalf or consulting with it. To improve transparency, GSK will publish these fees beginning in Q42009.
GSK provides grants and sponsorships to programs and organizations that help increase understanding of healthcare issues and the improvement of patient care. A report of the US payments was first published in February 2009.
To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.
For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.
